Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ACE-031 (ActRIIB-IgG1) in Healthy Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Ramatercept (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Acceleron Pharma
- 15 May 2014 New trial record